Researchers from Boston University School of Medicine (BUSM), in collaboration with researchers from the Inner City Asthma Consortium, have found that among inner-city children, the drug omalizumab improved asthma control, nearly eliminated seasonal exacerbations and reduced the need for controller medication. These findings appear in the March 17th issue of the New England Journal of Medicine. Guidelines-based treatment of persistent asthma follows a step-wise approach designed to achieve control...